BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

22 related articles for article (PubMed ID: 38433043)

  • 1. Chemotherapy treatments, costs of care, and survival for patients diagnosed with small cell lung cancer: A SEER-Medicare study.
    Shao C; He J; Kachroo S; Jin F
    Cancer Med; 2019 Dec; 8(18):7613-7622. PubMed ID: 31668011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Time-dependent cost comparison and health economic impact analysis of second-line interventions for transplant-ineligible patients with relapsed or refractory diffuse large B cell lymphoma.
    Kurte MS; Siefen AC; Jakobs F; Poos T; von Tresckow J; von Tresckow B; Reinhardt HC; Kron F
    Eur J Haematol; 2024 Jun; ():. PubMed ID: 38853698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ibrutinib and R-GemOx in patients with relapsed or refractory diffuse large B-cell lymphoma of non-GCB type: Phase II clinical trial of the Spanish GELTAMO group.
    Rey Búa B; Grande C; Sánchez Blanco JJ; Abrisqueta P; Gutiérrez A; Ramírez Páyer Á; Giné E; Zeberio Etxetxipia I; Terol MJ; de la Cruz Vicente F; Andreu R; Ramírez MJ; de la Fuente A; Viguria MC; Peñarrubia MJ; Jiménez-Ubieto A; Montes-Moreno S; Lopez-Guillermo A; Caballero MD; Martín García-Sancho A
    Clin Cancer Res; 2024 Jun; ():. PubMed ID: 38900037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidemiology and Real-World Treatment of Incident Diffuse Large B-cell Lymphoma (DLBCL): A German Claims Data Analysis.
    Pacis S; Bolzani A; Heuck A; Gossens K; Kruse M; Fritz B; Maywald U; Wilke T; Kunz C
    Oncol Ther; 2024 Jun; 12(2):293-309. PubMed ID: 38379108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mental health disorders and survival among older patients with diffuse large B-cell lymphoma in the USA: a population-based study.
    Kuczmarski TM; Tramontano AC; Mozessohn L; LaCasce AS; Roemer L; Abel GA; Odejide OO
    Lancet Haematol; 2023 Jul; 10(7):e530-e538. PubMed ID: 37271158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional status and therapy for older adults with diffuse large B-cell lymphoma in nursing homes: A population-based study.
    Di M; Keeney T; Belanger E; Huntington SF; Olszewski AJ; Panagiotou OA
    J Am Geriatr Soc; 2023 Jul; 71(7):2239-2249. PubMed ID: 36882865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab (MabThera) for aggressive non-Hodgkin's lymphoma: systematic review and economic evaluation.
    Knight C; Hind D; Brewer N; Abbott V
    Health Technol Assess; 2004 Sep; 8(37):iii, ix-xi, 1-82. PubMed ID: 15361313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world treatment patterns, survival, health resource use and costs among Medicare beneficiaries with diffuse large B-cell lymphoma.
    Garg M; Puckett J; Kamal-Bahl S; Raut M; Ryland KE; Doshi JA; Huntington SF
    Future Oncol; 2024 Feb; 20(6):317-328. PubMed ID: 38050764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct Costs Associated with Relapsed Diffuse Large B-Cell Lymphoma Therapies.
    Purdum A; Tieu R; Reddy SR; Broder MS
    Oncologist; 2019 Sep; 24(9):1229-1236. PubMed ID: 30850561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab plus gemcitabine and oxaliplatin (R-GemOx) in refractory/relapsed diffuse large B-cell lymphoma: a real-life study in patients ineligible for autologous stem-cell transplantation.
    Cazelles C; Belhadj K; Vellemans H; Camus V; Poullot E; Gaulard P; Veresezan L; Itti E; Becker S; Carvalho M; Dupuis J; Le Bras F; Lemonnier F; Roulin L; El Gnaoui T; Jardin F; Mounier N; Tilly H; Haioun C
    Leuk Lymphoma; 2021 Sep; 62(9):2161-2168. PubMed ID: 33764240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gemcitabine-oxaliplatin plus rituximab (R-GemOx) as first-line treatment in elderly patients with diffuse large B-cell lymphoma: a single-arm, open-label, phase 2 trial.
    Shen QD; Zhu HY; Wang L; Fan L; Liang JH; Cao L; Wu W; Xia Y; Li JY; Xu W
    Lancet Haematol; 2018 Jun; 5(6):e261-e269. PubMed ID: 29752199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health Care Resource Utilization and Total Costs of Care for Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia in the United States: A Retrospective Claims Analysis.
    Ito D; Feng C; Fu C; Kim C; Wu J; Dalton D; Epstein J; Snider JT; DuVall AS
    Clin Ther; 2024 Jan; 46(1):3-11. PubMed ID: 37981560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-World Survival, Healthcare Resource Utilization, and Costs Among U.S. Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL) Treated With R-GemOx in the Relapsed/Refractory Setting.
    Garg M; Puckett J; Kamal-Bahl S; Raut M; Ryland KE; Doshi JA; Huntington SF
    Clin Lymphoma Myeloma Leuk; 2024 May; 24(5):e181-e190. PubMed ID: 38433043
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.